Qbic II
Overview
Qbic II is a Belgian venture capital fund that focuses on transforming technological breakthroughs into sustainable businesses. It primarily invests in spin-offs and start-ups that have a strong connection to Qbic's partner universities and research institutions. The fund typically participates in the first external investment round of a company and continues to support these companies throughout their growth. The fund's investment strategy is sector-agnostic, supporting a diverse range of industries, including Biotech, HealthTech, DeepTech, and Software. Qbic II has a fund size of €58.9 million and has invested in 19 ventures. The investment period for Qbic II ended in 2022, and the fund is now focusing on follow-on investments and exits. Qbic II is managed by an independent team of seasoned investment and business professionals. The fund is one of the largest inter-university spin-off funds in Europe, with close to €100 million under management across its different funds. It collaborates with a network of Belgian universities, research institutes, and hospitals, providing early and privileged access to promising research projects at these partner institutions.
Investment Focus
- Strong connection to Qbic's partner universities and research institutions
- Innovative business models with high growth potential
Portfolio Companies
Reach Qbic II directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Qbic II
What sectors does Qbic II invest in?
Qbic II invests in Software, HealthTech, Biotech and DeepTech, and is based in East Flanders, Belgium. Qbic II is listed as a venture capital in the ConnectSafely investor database.
What stage does Qbic II invest at?
Qbic II backs companies at Seed and Early Stage, writing cheques of 100K - 1.5M.
Which regions does Qbic II invest in?
Qbic II invests across Belgium.
What companies has Qbic II invested in?
Qbic II's portfolio includes Spica Therapeutics, Aloxy, MRM Health, Blue Foot, Trince, AmphiStar, Flindr and Innocens.
Last updated · Source: ConnectSafely investor database




